Managing Moderate-to-Severe Psoriasis in the Elderly

被引:0
作者
Nicola Balato
Cataldo Patruno
Maddalena Napolitano
Angela Patrì
Fabio Ayala
Raffaele Scarpa
机构
[1] University of Naples Federico II,Department of Dermatology
[2] University of Naples Federico II,Department of Rheumatology
来源
Drugs & Aging | 2014年 / 31卷
关键词
Psoriasis; Infliximab; Etanercept; Adalimumab; Ustekinumab;
D O I
暂无
中图分类号
学科分类号
摘要
Managing psoriasis in the elderly can be difficult for physicians, who must consider comorbidities, the resulting polypharmacy, and progressive functional impairment of several organs. Indeed, topical agents are the first-line treatment for limited disease. Phototherapy is recommended if topical drugs are not sufficient and the patient has multiple comorbidities and risk factors that make them a poor candidate for an oral or injectable systemic agent. The most important pharmacokinetic alteration in the elderly population is the decreased excretory capacity of the kidney; thus, cyclosporine should be considered a last resort treatment, and the administered dose of methotrexate should be lowered according to the reduction in estimated creatinine clearance. Acitretin can be used in the absence of severe renal insufficiency, paying attention to lipid profile, treating eventual hyperlipidemia, and closely monitoring liver enzymes. Available data on biological drugs in the elderly are limited. Biologics are associated with a small but significant overall risk of infections. However, there is no convincing evidence that the relative risk of infection with anti-tumor necrosis factor (TNF)-α therapy increases with age. Nevertheless, the package inserts for biologics recommend caution when administering these medications to the geriatric population, due to the high baseline risk of infection in such patients. Etanercept seems to be well tolerated, possibly because of its lower immunosuppressive characteristics compared with other biologics. However, studies with larger sample sizes are needed to confirm its safety.
引用
收藏
页码:233 / 238
页数:5
相关论文
共 163 条
[11]  
Antoniou C(2007)UVB therapy increases 25(OH) vitamin D syntheses in postmenopausal women with psoriasis Photodermatol Photoimmunol Photomed 23 172-802
[12]  
Arenberger P(1989)Methotrexate dosage in patients aged over 50 with psoriasis BMJ 298 801-260
[13]  
Balieva F(1992)The efficacy of methotrexate in psoriasis—a review of 40 cases Clin Exp Dermatol 17 257-519
[14]  
Bylaite M(2006)Etanercept for the treatment of psoriasis in the elderly J Am Acad Dermatol 55 517-456
[15]  
Correia O(2010)Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis J Am Acad Dermatol 63 448-131
[16]  
Daudén E(2011)Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly Rheumatology 50 124-384
[17]  
Gisondi P(2006)Long term safety of etanercept in elderly subjects with rheumatic diseases Ann Rheum Dis 65 379-215
[18]  
Iversen L(2006)Drug dosage in the elderly: dermatological drugs Drugs Aging 23 203-1003
[19]  
Kemény L(2013)Changes in pharmacokinetics in elderly patients Nihon Rinsho 71 999-283
[20]  
Lahfa M(2005)Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalized for psoriasis Eur J Dermatol 15 279-392